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Purpose: To screen cytochrome P4501B1 (CYP1B1) for causative mutations in Omani patients with a clinical diagnosis
of primary congenital glaucoma (PCG)
Methods: Nine PCG families were recruited for the study. All patients underwent detailed clinical examinations to confirm
the diagnosis of PCG. The families of index patients were also examined. Genealogical information was obtained by
pedigree analysis. The primary candidate gene, CYP1B1, was amplified from genomic DNA, sequenced, and analyzed in
patients to identify the disease-causing mutations.
Results: Eight of the nine PCG families were consanguineous (89%). Molecular analysis of CYP1B1 showed three distinct
mutations, p.G61E, p.D374N, and p.R368H, in seven of nine unrelated PCG index patients (78%). Six patients had
homozygous mutations and one had a compound heterozygous mutation. Causative mutations were not identified in two
families. In family 4, the index patient was found to be heterozygous for the p.E229K variant. In family 6, although affected
individuals were found to be homozygous in the CYP1B1 region, no mutation could be identified.
Conclusions: This study indicates that CYP1B1 could be the predominant cause of PCG in the Omani population (78%).
Omani PCG patients show allelic heterogeneity. Further studies are needed to delineate the spectrum of CYP1B1mutations
in Omani PCG families and to identify new or modifier genes contributing to the manifestations of PCG in this region.
Primary  congenital  glaucoma  (PCG;  OMIM  231300;
gene symbol, GLC3) is characterized by congenital elevation
of intraocular pressure (IOP) consequent to impaired aqueous
outflow via the trabecular meshwork. While uncommon in the
West (less than 1 in 30,000 live births), PCG is relatively
common in the Middle East with an estimated incidence of 1
in  2,500  live  births.  This  is  partly  attributed  to  the  high
incidence of consanguineous marriages in this region [1]. In
Saudi Arabia, a neighboring state of Oman, PCG has been
found to be the predominant cause for childhood blindness
[1].
Clinically,  PCG  is  unassociated  with  other  ocular  or
systemic diseases and is divided into three subsets, newborn
PCG (patients recognized at birth or in the first month of life),
infantile PCG (patients presenting in the first two years of
life), and juvenile PCG (patients diagnosed after two years of
age) [2]. More than 80% of the cases present within the first
year of life with 25% diagnosed in the neonatal period and
60% within the first six months of life [3]. In 75% of cases,
both eyes are involved, and males are affected somewhat more
often than females [4].
The disease is characterized by high IOP, buphthalmos,
megalocornea,  and  breaks  in  Descemet’s  membrane  with
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corneal  opacification.  PCG  in  the  Middle  East  is  more
aggressive and is associated with poorer therapeutic outcomes
than in the West [5,6].
About 10% of all PCG cases are inherited, the mode of
inheritance being largely autosomal recessive with variable
penetrance.  Strong  inheritance  (vertical  transmission)  is
rarely  observed  in  some  families  and  is  explained  by
pseudodominance [7]. Three chromosomal regions, 2p21 at
locus GLC3A [8,9], 1p36 at locus GLC3B [10], and 14q24.3
at locus GLC3C [11] have been reported to be associated with
PCG. The only identified gene so far is CYP1B1 at locus
GLC3A, and this gene encodes for cytochrome P450 1B1 [8,
9]. This enzyme is a cell membrane bound monomeric mixed-
function oxygenase believed to interact with an arachidonate
metabolite that is important for the normal development and
function of the anterior segment of the eye [12].
To date, more than 60 mutations associated with PCG and
a few polymorphisms in CYP1B1 have been found [13], one
third  of  them  being  deletions  or  insertions,  implying  an
inherited instability of the gene. A total of six common single
nucleotide polymorphisms (SNPs) have been identified in the
CYP1B1 region, one upstream of exon 2 (rs2617266) and five
coding  SNPs  (rs10012  [p.  R48G],  rs1056827  [p.A119S],
rs1056836 [p.V432L], rs1056837 [p.D449D], and rs1800440
[p.N453S]) [11]. These SNPs are embedded in a CYP1B1
region in linkage disequilibrium [14].
There is a high incidence of consanguinity in Oman (up
to  36%),  which  leads  to  a  high  prevalence  of  autosomal
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1325recessive diseases in the country [15]. To date, the genetic
basis and prevalence of various mutations among Omani PCG
patients has not been studied. We report the results of a pilot
study to determine the distribution of CYP1B1 mutations in
Omani patients with PCG.
METHODS
This  research  was  performed  in  accordance  with  the
Declaration of Helsinki and with the approval of the Medical
Research Ethics Committee of the Sultan Qaboos University
(Muscat, Oman). The families of nine patients consented to
participate after being informed of the nature of the research.
PCG patients who were registered in the ocular genetics
database of the Department of Ophthalmology, SQUH, Oman
were recalled. Patients with ocular abnormalities or systemic
diseases suggestive of secondary glaucoma such as aniridia,
anterior segment dysgenesis, Lowe syndrome, and Sturge-
Weber syndrome were excluded from the study.
All patients were examined by at least one of the authors
(A.G., S.E., S.Z., A.B.), either in the office awake or sedated,
or underwent an examination under anesthesia. Ophthalmic
examination  included  evaluation  of  best-corrected  visual
acuity  (with  age-appropriate  tests),  corneal  diameter,  IOP
(with Tonopen XL or Perkins tonometer), corneal thickness
(with ultrasound pachymeter), cup-disc ratio (with indirect
ophthalmsocopy  with  +20D),  and  axial  length  (with
ultrasound biometry). IOP values were corrected for corneal
thickness  based  on  nomograms.  Slit  lamp  examination,
gonioscopy, visual field evaluation (automated visual field
Humphrey 24–2 or Goldman) and fundus photography were
done  when  feasible.  Glaucoma  was  diagnosed  if  patients
demonstrated an IOP ≥22 mmHg with other signs of PCG
including  buphthalmos,  megalocornea,  corneal  edema,
Haab’s striae, and increased cup/disc ratio.
Genealogical  information  was  obtained  by  pedigree
analysis. The siblings, parents, and other family members
suspected to have PCG were clinically examined along with
the proband.
Genomic DNA was extracted from peripheral blood. The
two  coding  exons  of  CYP1B1  were  amplified  using  four
previously published primer pairs [16]. For amplification, a
touchdown polymerase chain reaction (PCR) program was
used with annealing temperature decreasing from 65 °C to
55  °C  over  nine  cycles  followed  by  24  cycles  with  an
annealing temperature of 55 °C in a 25 μl mixture (PCR
conditions available on request). Sequencing reactions were
performed  on  both  strands  using  the  BigDye  Terminator
Cycle Sequencing Kit v3.1 (Applied Biosystems, Foster City,
CA)  according  to  the  manufacturer’s  instructions.  The
products were analyzed on an ABI Genetic Analyzer 3730
(Applied  Biosystems).  Using  segregation  analysis  in  the
families, haplotypes were constructed using the six previously
mentioned common SNPs in the gene, one upstream of exon
2 (rs2617266) and five coding SNPs (rs10012 [p. R48G],
rs1056827  [p.A119S],  rs1056836  [p.V432L],  rs1056837
[p.D449D], and rs1800440 [p.N453S]) [11]. Mutations when
found were confirmed in family members.
RESULTS
Nine patients with PCG (5 males, 4 females) and their families
were enrolled in the study. All affected patients had IOPs
greater than or equal to 21 mmHg as well as increased corneal
diameters (>12mm), cup-disc ratios, and axial lengths. All
patients included in the present study had an aggressive form
of glaucoma with onset within the first month of life and had
undergone multiple surgical interventions for control of their
glaucoma. The clinical data are summarized in Table 1 and
Table 2.
Consanguinity was found in eight of the nine families
(89%)  without  any  gender  preference  (Table  3).  In  five
families,  more  than  one  individual  was  affected.  The
presumed mode of inheritance according to pedigree analysis
was autosomal recessive in all families. Molecular analysis of
CYP1B1  permitted  the  identification  of  three  causative
mutations in seven of the nine index cases (78%; Table 3).
The p.G61E, p.D374N, and p.R368H mutations have all been
previously reported as disease-causing mutations [1,17]. The
identified mutations were homozygous in six patients and
compound  heterozygous  in  one  patient  (Table  3).  The
mutations segregated with the disease in the seven families.
The index case in family 4 presented the previously reported
risk-associated but not clearly disease-causing [18] p.E229K
variant in heterozygous form. Haplotype analysis for family
4 using the six coding SNPs in CYP1B1 ruled out this variant
as the cause of PCG (Figure 1A). It did not segregate with the
disease since the affected brother of the index patient (II.1)
did not carry the variant. No mutation in CYP1B1 could be
identified  for  family  6  (Table  3).  Haplotype  analysis,
however, suggested linkage to the CYP1B1 locus, GLC3A
(Figure 1B). Both affected individuals (II.2 and II.3) were
homozygous for the same SNP haplotype, 5′-CCGGTA-3′,
while their unaffected sister was heterozygous. Thus, a total
of 14 mutations and one risk-associated variant were found in
the nine patients representing an overall mutation rate of 14
in 18 (78%) studied chromosomes.
DISCUSSION
PCG is a genetically heterogeneous disorder that maps to at
least three different loci. However, in the majority of PCG
patients, the candidate locus has been found to be GLC3A,
which codes for a cytochrome p450 protein called CYP1B1
[9]. Among patients with PCG, the proportion of patients due
to CYP1B1 mutations is variable across populations from
~100%  among  Saudi  Arabians  [1,17]  and  Slovakgypsies
(Roms) [19] to ~20% in Japanese [20]. We detected three
distinct disease-causing CYP1B1 mutations in seven of the
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1328nine  PCG  index  patients  (78%).  Our  results  indicate  that
CYP1B1 mutations play a crucial role in Omani PCG patients
as in other Arab populations.
The worldwide profile of variations in the coding region
of  CYP1B1  in  patients  with  PCG  thus  far  reported  is
heterogeneous and includes ~70 alterations (Human Genome
Mutation  Database)  [21].  However,  the  Slovakgypsies
(Roms) and Saudi Arabian patients with PCG exhibit allelic
homogeneity that has largely been attributed to consanguinity
and inbreeding [17,19]. The detection of three disease-causing
mutations in seven index cases indicates that Omani PCG
patients show allelic heterogeneity. The three mutations we
found in Omani patients (p.R368H, p.D374N, and p.G61E)
have been reported as the most common mutations in the
Saudi population, accounting for 72%, 12%, and 7% of the
tested alleles, respectively [1,17]. Oman has been a major
gateway in human history with evidence of clear contacts with
sub-Saharan West Africa, East Africa (Zanzibar/Mombasa),
Iraq, Iran, Pakistan, and India and is expected to have a rich
genetic legacy. The degree of heterogeneity within different
populations as well as the distribution of mutations have been
seen to be very variable and are believed to be attributable to
variations  in  gene  pools  among  the  different  populations
[22].
Among the seven index cases with CYP1B1 mutations,
one  carried  two  different  mutations  (compound
heterozygous). The large proportion of Omani PCG patients
(6/7; 86%) carrying homozygous mutations in CYP1B1 is
indicative  of  extensive  consanguineous  marriages  in  the
Omani population.
The p.E229K variant found in family 4 did not segregate
with the disease (Table 3, Figure 1A). Haplotype analysis
suggested that mutations in a locus different than GLC3A
could be responsible for PCG in this family. In family 6,
(Table  3,  Figure  1B)  no  mutation  could  be  identified.
However, both affected individuals were homozygous in the
CYP1B1  region,  making  it  likely  that  a  mutation  in  the
promoter or in some other regulatory region of the gene is
responsible  for  the  disease.  Further  work  with  family  4
(performing  a  linkage  analysis  after  recruiting  additional
affected and healthy family members) and family 6 (analysis
of cDNA in the affected family members) is in progress.
Our study is the first report of molecular genetic analysis
of PCG in the Omani population. To verify the results of this
pilot study, to further delineate the role of CYP1B1 mutations
in the pathogenesis of PCG in the Omani population, and to
identify  new  or  modifier  genes  contributing  to  the
manifestations of PCG in this region, further studies with a
TABLE 2. CLINICAL DETAILS IN STUDY PATIENTS WITH PRIMARY CONGENITAL GLAUCOMA II.
Clinical Parameter Data Range (n=18 PCG patients)
Age of onset at birth–1 month*
Age at diagnosis at birth–12 years
Age currently 6 months–26 years
Corneal diameter horizontally [mm] 9–19
Intraocular pressure [mmHg] 12–45
Cup-disk ratio 0.0–1.0
Axial length [mm] 18.47->30 (and phthisis bulbi in some cases)
Pachymetry central [µm] 465–816
Refraction as spherical equivalent [D] +0.5 to −11.9
Visual acuity [decimal] No Light Perception–1.0
All data refer to time of last examination except where stated differently. The asterisk denotes that in two PCG patients, the age
of onset was unclear (but definitely within one year of age). PCG-primary congenital glaucoma.
TABLE 3. CYP1B1 MUTATIONS ASSOCIATED WITH PRIMARY CONGENITAL GLAUCOMA IN OMANI PATIENTS.
Family
number Consanguinity Number of affected individuals Gender
Mutations
Exon Allele 1 Allele 2
1 No 1 Male p.R368H p.R368H III
2 Yes 4 Female p.D374N p.D374N III
3 Yes 1 Female p.G61E p.G61E II
4 Yes 2 Female p.E229K no mutation II
5 Yes 1 Male p.G61E p.R368H II/III
6 Yes 2 Male no mutation no mutation
7 Yes 3 Male p.D374N p.D374N III
8 Yes 4 Female p.G61E p.G61E II
9 Yes 1 Male p.R368H p.R368H III
Consanguinity was found in eight of the nine families (89%). In five families, more than one individual was affected. Molecular
analysis of CYP1B1 permitted the identification of three causative mutations in seven of the nine index cases (78%).
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1329larger sample of patients are being planned. Identifying the
mutation spectrum of CYP1B1 that causes PCG in the Omani
population has implications in devising molecular diagnostics
for rapid screening in predisposed families that would aid in
early intervention.
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